According to the research report, the global type 2 diabetes market size is expected to touch USD 61.6 Billion by 2030, from USD 32.31 Billion in 2022, growing with a significant CAGR of 8.4% from 2022 to 2030.
The type 2 diabetes report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global type 2 diabetes in conjunction
with the geographical landscape of this vertical have also been included in
this report.
The report offers intricate dynamics about
different aspects of the global type 2 diabetes market, which aids companies
operating in the market in making strategic development decisions. The study
also elaborates on significant changes that are highly anticipated to configure
growth of the global type 2 diabetes during the forecast period. It also
includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1663
| Report Coverage | Details |
| Market Size by 2030 | USD 61.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.4% |
| North America Market Share in 2021 | 35% |
| Fastest growing Region | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Application, Geography |
This study covers a detailed segmentation
of the global type 2 diabetes market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global type 2 diabetes market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Amgen Inc.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Co. Ltd
- Eli Lilly and Co.
- Merck & Co. Inc
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd
Market Segmentation
- Dipeptidyl Peptidase-4
- Inhibitors
- Glucagon-Like Peptide
- Receptor Agonists
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Sulfonylureas
- Secretagogues
- Biguanides
- Sodium Glucose Cotransport 2 Inhibitors
By Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global type 2 diabetes report is based on detailed
primary as well as secondary research. With the help of in-depth insights of
the market-affiliated information that is obtained and legitimated by
market-admissible resources, analysts have offered riveting observations and authentic
forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global type 2 diabetes market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Type 2 Diabetes Market
5.1. COVID-19 Landscape: Type 2 Diabetes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Type 2 Diabetes Market, By Drug Class
8.1. Type 2 Diabetes Market, by Drug Class Type, 2022-2030
8.1.1. Dipeptidyl Peptidase-4
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Inhibitors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Glucagon-Like Peptide
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Receptor Agonists
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Thiazolidinediones
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Alpha-Glucosidase Inhibitors
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Sulfonylureas
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Secretagogues
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Biguanides
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Sodium Glucose Cotransport 2 Inhibitors
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Type 2 Diabetes Market, By Application
9.1. Type 2 Diabetes Market, by Application, 2022-2030
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Type 2 Diabetes Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
Chapter 11. Company Profiles
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca PLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Boehringer Ingelheim International GmbH
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Daiichi Sankyo Co. Ltd
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Eli Lilly and Co.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Merck & Co. Inc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novo Nordisk AS
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi SA
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Takeda Pharmaceutical Co. Ltd
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments